At a glance
ClinicalIndex Comparison RecordPhase 2Suspended· 216 target
Drug / intervention
8MW2311drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating 8MW2311 for Solid Tumors. Suspended, targeting 216 participants across 3 sites.
Signals
Trial is currently suspended
Detailed Summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV) infusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2SuspendedOverdue
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionMar 2026
TodayJul 2026
First PostedJun 13, 2022
Enrollment StartAug 5, 2022
Primary CompletionMar 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 4.0 years ago
Interventions
8MW2311drug
All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.